Loading organizations...
§ Private Profile · Madison, WI, USA
biotechnology company developing universal influenza vaccines, antiviral peptides, and cell culture manufacturing.
Founded in 2007 by Yoshihiro Kawaoka, Gabriele Neumann, and Paul Radspinner, FluGen is a Madison, Wisconsin-based biotechnology company developing novel influenza vaccines and antiviral treatments. The enterprise focuses on transitioning vaccine manufacturing from traditional embryonated eggs to more efficient cell culture methods while creating universal M2SR vaccines for a global market historically estimated at over $3 billion. Operating with a reported headcount of eight employees, the firm has successfully completed multiple human clinical trials to advance its proprietary entry-blocker antiviral peptides. The venture-backed private business has raised over $40 million in total capital, including a $12 million Series A financing round backed by Venture Investors LLC, the Wisconsin Alumni Research Foundation, and the State of Wisconsin Investment Board. The organization also added experienced industry executives Dan Stinchcomb and Boyd Clarke to its board of directors.
FluGen has raised $12.0M across 1 funding round.
FluGen has raised $12.0M in total across 1 funding round.
FluGen has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Series A in August 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 25, 2015 | $12M Series A | Paul Weiss | Knox, State OF Wisconsin Investment Board, Warf Ventures | Announced |
FluGen has raised $12.0M in total across 1 funding round.
FluGen's investors include Paul Weiss, Knox, State of Wisconsin Investment Board, WARF Ventures.